Pirfenidone: an anti-fibrotic therapy for progressive kidney disease (Q34680788)

3 August 2017

1 reference

title

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease (English)

1 reference

3 August 2017

Jeffrey B Kopp

2

0 references

author name string

Monique E Cho

series ordinal

1

1 reference

PubMed ID

20050822

3 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Investigational Drugs

3 August 2017

1 reference

3 August 2017

19

1 reference

3 August 2017

2

1 reference

3 August 2017

275-283

1 reference

Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone is renoprotective in diabetic kidney disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Overview of factors contributing to the pathophysiology of progressive renal disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

A pilot study in patients with established advanced liver fibrosis using pirfenidone

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone for the treatment of idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Inhibitory smads and tgf-Beta signaling in glomerular cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

TGF-beta signaling in renal disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone in the treatment of primary sclerosing cholangitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone improves renal function and fibrosis in the post-obstructed kidney

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Cyclosporine stimulates expression of transforming growth factor-beta in renal cells. Possible mechanism of cyclosporines antiproliferative effects.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Transforming growth factor-beta 1 induces extracellular matrix formation in glomerulonephritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation

7 July 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3058482

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

26 October 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501539

Phase II trial of pirfenidone in adults with neurofibromatosis type 1

21 January 2018

1 reference

12 December 2020

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas

1 reference

12 December 2020

It's a Smad world: regulation of TGF-beta signaling in the kidney

1 reference

12 December 2020

In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine

1 reference

12 December 2020

Increased renal production of transforming growth factor-beta1 in patients with type II diabetes

1 reference

12 December 2020

Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy

1 reference

12 December 2020

Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy

1 reference

12 December 2020

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

1 reference

12 December 2020

Role of transforming growth factor beta in diabetic nephropathy

1 reference

12 December 2020

10.1517/13543780903501539

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

PubMed ID

20050822